Testing VT-101 for Advanced Ovarian Cancer in Adult Women
Tests the investigational drug VT-101 in adult women with advanced ovarian cancer.
Plain-language title generated from the registry record
Registry title: Phase 1 Study of VT-101 in Advanced Ovarian Cancer
Key facts
- Where
- Iowa City, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07905677, who can take part
Where in United States
- University of Iowa Health CareIowa City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Michael J. Goodheart
- Trial code
- NCT07905677
- Record updated
- 9 November 2026
- Original description
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.Read full original descriptionShow less
A Phase 1 Dose-Finding, Safety, and Preliminary Clinical Activity Study of VT-101 in Advanced Ovarian Cancer
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.
Inclusion: Female participant; Age ≥ 18 years; Histologically confirmed advanced, recurrent, or relapsed epithelial ovarian cancer; Has received prior standard therapy for ovarian cancer, OR has refused standard therapy, OR is intolerant to standard therapy, OR is not eligible for standard therapy; ECOG Performance Status of 0, 1, or 2; Adequate bone marrow, liver, and kidney function as defined by the protocol; Able to comply with study procedures and provide informed consent; For women of childbearing potential: agrees to use protocol-required contraception and meets pregnancy testing requirements.
Exclusion: Participants must have advanced, recurrent, or relapsed epithelial ovarian cancer; Medical conditions or laboratory abnormalities that would make study participation unsafe; Female only; Age:; No upper age limit specified; Healthy Volunteers:; Does not meet the inclusion criteria; Other protocol-defined exclusions as determined by the investigator; Sex:; 18 years and older; No; Healthy volunteers are not eligible.
ELIGIBILITY CRITERIA.